Allogeneic hematopoietic cell transplantation in mantle cell lymphoma

• Published in: Best practice & research. Clinical haematology Vol. 25; no. 2; pp. 165 - 174
• Main Authors: Cassaday, Ryan D., MD, Gopal, Ajay K., MD
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier Ltd 01.06.2012
• Subjects: allogeneic transplantation; Antineoplastic Agents - administration & dosage; Antineoplastic Agents - therapeutic use; Disease Management; Epidemiologic Studies; Graft vs Host Disease - immunology; Graft vs Host Disease - therapy; Graft vs Tumor Effect - immunology; Hematology, Oncology and Palliative Medicine; Hematopoietic Stem Cell Transplantation - methods; Humans; Lymphoma, Mantle-Cell - immunology; Lymphoma, Mantle-Cell - therapy; mantle cell lymphoma; Myeloablative Agonists - administration & dosage; Myeloablative Agonists - therapeutic use; Recurrence; Transplantation, Homologous; Treatment Outcome; mantle cell lymphoma; allogeneic transplantation
• ISSN: 1521-6926; 1532-1924
• DOI: 10.1016/j.beha.2012.04.002

Mantle cell lymphoma (MCL) is a high-risk non-Hodgkin lymphoma that is considered incurable with standard chemotherapy. While autologous hematopoietic cell transplantation (autoHCT) can provide lengthy disease-free survival in select patients, cure generally is not an expected outcome with this approach. Allogeneic hematopoietic cell transplantation (alloHCT), which can exploit the potential benefits of graft- versus -lymphoma (GVL) effect, has been shown in multiple studies to yield a small but reproducible portion of patients with long-term remission more suggestive of cure. Historically, alloHCT for MCL was administered after myeloablative conditioning, but this approach was limited by early non-relapse mortality. Development of reduced-intensity (RI)-alloHCT has abrogated some of the early post-transplant risks, allowing this potentially effective therapy to be offered to a larger number of affected individuals. The trends in published data reflect a preference toward using RI-alloHCT for MCL, often because patients in whom alloHCT is being considered have relapsed disease following myeloablative autoHCT. Further efforts to spare the effects of graft- versus -host disease (GVHD) while still evoking GVL remain a focus of investigation in this area. In this review, we will discuss the application of alloHCT in the management of MCL, the factors associated with outcome, the different methods in which it can be performed, and the strategies that can be employed in post-alloHCT relapse.